{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:29:03Z","timestamp":1790126943952,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40261-026-01573-9","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:55:04Z","timestamp":1782730504000},"page":"931-964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review"],"prefix":"10.1007","volume":"46","author":[{"given":"Jacob","family":"Surma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzy","family":"Maddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Borgman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"DeGroat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Demarinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Fakhoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stachler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1573_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, Huang Y, Wang L, Yao X, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190:55\u201361. https:\/\/doi.org\/10.1093\/bjd\/ljad339.","journal-title":"Br J Dermatol"},{"key":"1573_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13, and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17:835\u201352. https:\/\/doi.org\/10.1080\/1744666X.2021.1940962.","journal-title":"Expert Rev Clin Immunol"},{"key":"1573_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13899","volume":"17","author":"MR McCann","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: Mechanism of action, clinical, and translational science. Clinical Translational Sci. 2024;17:e13899. https:\/\/doi.org\/10.1111\/cts.13899.","journal-title":"Clinical Translational Sci."},{"key":"1573_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/pch\/6.8.555","volume":"6","author":"Z Chad","year":"2001","unstructured":"Chad Z. Allergies in children. Paediatr Child Health. 2001;6:555\u201366. https:\/\/doi.org\/10.1093\/pch\/6.8.555.","journal-title":"Paediatr Child Health"},{"key":"1573_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.5664\/jcsm.27992","volume":"6","author":"D Camfferman","year":"2010","unstructured":"Camfferman D, Kennedy JD, Gold M, Martin AJ, Winwood P, Lushington K. Eczema, sleep, and behavior in children. J Clin Sleep Med. 2010;6:581\u20138.","journal-title":"J Clin Sleep Med"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.2340\/actadv.v103.5268","volume":"103","author":"L Beckman","year":"2023","unstructured":"Beckman L, Hagquist C, Svensson \u00c5, Langan SM, Von Kobyletzki L. Relationship between eczema and self-reported difficulties keeping up with school education: a cross-sectional study. Acta Derm Venereol. 2023;103:5268. https:\/\/doi.org\/10.2340\/actadv.v103.5268.","journal-title":"Acta Derm Venereol"},{"key":"1573_CR7","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/ijerph19052652","volume":"19","author":"S Plaza-Gonz\u00e1lez","year":"2022","unstructured":"Plaza-Gonz\u00e1lez S, Zabala-Ba\u00f1os MDC, Astasio-Picado \u00c1, Jurado-Palomo J. Psychological and sociocultural determinants in childhood asthma disease: impact on quality of life. IJERPH. 2022;19:2652. https:\/\/doi.org\/10.3390\/ijerph19052652.","journal-title":"IJERPH."},{"key":"1573_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3390\/children8111057","volume":"8","author":"KA Kelly","year":"2021","unstructured":"Kelly KA, Balogh EA, Kaplan SG, Feldman SR. Skin disease in children: effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients. Children. 2021;8:1057. https:\/\/doi.org\/10.3390\/children8111057.","journal-title":"Children"},{"key":"1573_CR9","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024) [Internet]. Cochrane; 2024. www.cochrane.org\/handbook"},{"key":"1573_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37:387\u2013387. https:\/\/doi.org\/10.1136\/emermed-2020-209567.","journal-title":"Emerg Med J"},{"key":"1573_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100.","journal-title":"PLoS Med"},{"key":"1573_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1573_CR13","unstructured":"Hong QN, Pluye P, F\u00e0bregues S, Barlett G, Boardman F, Cargo M. Mixed Methods Appraisal Tool (MMAT), version 2018. National Collaborating Centre for Methods and Tools; 2018."},{"key":"1573_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/pde.14980","volume":"39","author":"SA Havele","year":"2022","unstructured":"Havele SA, Khurana MC, McMahon P, Murthy AS, Perman MJ, Treat JR. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis. Pediatr Dermatol. 2022;39:291\u20134. https:\/\/doi.org\/10.1111\/pde.14980.","journal-title":"Pediatr Dermatol"},{"key":"1573_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/pde.14996","volume":"39","author":"D Mazzoni","year":"2022","unstructured":"Mazzoni D, Lobo Y, Levitt D, Wheller L. Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab. Pediatr Dermatol. 2022;39:606\u20138. https:\/\/doi.org\/10.1111\/pde.14996.","journal-title":"Pediatr Dermatol"},{"key":"1573_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/pde.14970","volume":"39","author":"M Rao","year":"2022","unstructured":"Rao M, Grove D, Haggstrom A. A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis. Pediatr Dermatol. 2022;39:288\u201390. https:\/\/doi.org\/10.1111\/pde.14970.","journal-title":"Pediatr Dermatol"},{"key":"1573_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/pde.15418","volume":"41","author":"S Martinez-Cabriales","year":"2024","unstructured":"Martinez-Cabriales S, Marcoux D, Liy-Wong C, Prajapati VH, Sibbald C, Cunningham N, et al. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab. Pediatr Dermatol. 2024;41:5\u201311. https:\/\/doi.org\/10.1111\/pde.15418.","journal-title":"Pediatr Dermatol"},{"key":"1573_CR18","doi-asserted-by":"publisher","unstructured":"Votto M, Delle Cave F, De Filippo M, Marseglia A, Marseglia GL, Brazzelli V, et al. Rapid response to dupilumab treatment in children with moderate\u2010to\u2010severe atopic dermatitis: A case series. Del Giudice MM, editor. Pediatric Allergy Immunology. 2022;33:31\u20133. https:\/\/doi.org\/10.1111\/pai.13623","DOI":"10.1111\/pai.13623"},{"key":"1573_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400:908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000535282","volume":"240","author":"E Berna-Rico","year":"2024","unstructured":"Berna-Rico E, Fiz-Benito E, Busto-Leis JM, Servera-Negre G, De Lucas-Laguna R, Feito-Rodriguez M. Effectiveness and safety of dupilumab in children under 6 years of age with moderate-to-severe atopic dermatitis: a retrospective real-world study. Dermatology. 2024;240:337\u201342. https:\/\/doi.org\/10.1159\/000535282.","journal-title":"Dermatology"},{"key":"1573_CR21","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1111\/jdv.18450","volume":"36","author":"A Lasek","year":"2022","unstructured":"Lasek A, Bellon N, Mallet S, Puzenat E, Bursztejn AC, Abasq C, et al. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6\u201311 years): data from a French multicentre retrospective cohort in daily practice. Acad Dermatol Venereol. 2022;36:2423\u20139. https:\/\/doi.org\/10.1111\/jdv.18450.","journal-title":"Acad Dermatol Venereol"},{"key":"1573_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40272-022-00531-0","volume":"24","author":"M Napolitano","year":"2022","unstructured":"Napolitano M, Fabbrocini G, Neri I, Stingeni L, Boccaletti V, Piccolo V, et al. Dupilumab treatment in children aged 6\u201311 years with atopic dermatitis: a multicentre. Real-Life Study Pediatr Drugs. 2022;24:671\u20138. https:\/\/doi.org\/10.1007\/s40272-022-00531-0.","journal-title":"Real-Life Study. Pediatr Drugs."},{"key":"1573_CR23","doi-asserted-by":"publisher","first-page":"2246602","DOI":"10.1080\/09546634.2023.2246602","volume":"34","author":"C Patruno","year":"2023","unstructured":"Patruno C, Fabbrocini G, Lauletta G, Boccaletti V, Colonna C, Cavalli R, et al. A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years. J Dermatol Treat. 2023;34:2246602. https:\/\/doi.org\/10.1080\/09546634.2023.2246602.","journal-title":"J Dermatol Treat"},{"key":"1573_CR24","doi-asserted-by":"publisher","first-page":"1160710","DOI":"10.3389\/fimmu.2023.1160710","volume":"14","author":"A Wang","year":"2023","unstructured":"Wang A, Zhou Y, Luo Y, Gao Y, Chen J, Li W, et al. High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710. https:\/\/doi.org\/10.3389\/fimmu.2023.1160710.","journal-title":"Front Immunol"},{"key":"1573_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00403-022-02380-w","volume":"315","author":"D-Y Yang","year":"2022","unstructured":"Yang D-Y, Li L, Lu T, Jing W-W, Liu X, Li X-L. Efficacy, and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study. Arch Dermatol Res. 2022;315:467\u201372. https:\/\/doi.org\/10.1007\/s00403-022-02380-w.","journal-title":"Arch Dermatol Res"},{"key":"1573_CR26","doi-asserted-by":"publisher","unstructured":"Yang N, Ye Y, Shao J, Wu H, Xu Q, Zhu J, et al. Efficacy of Dupilumab in Children 6 Months to 11 Years Old with Atopic Dermatitis: A Retrospective Real-World Study in China. Dermatitis\u00ae [Internet]. 2024 [cited 2026 Mar 28];35. https:\/\/doi.org\/10.1089\/derm.2022.0069","DOI":"10.1089\/derm.2022.0069"},{"key":"1573_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, et al. Dupilumab provides favourable long\u2010term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open\u2010label phase IIa study and subsequent phase III open\u2010label extension study. Br J Dermatol. 2021;184:857\u201370. https:\/\/doi.org\/10.1111\/bjd.19460.","journal-title":"Br J Dermatol"},{"key":"1573_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.16928","volume":"35","author":"AS Paller","year":"2021","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, et al. A phase 2, open\u2010label study of single\u2010dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Acad Dermatol Venereol. 2021;35:464\u201375. https:\/\/doi.org\/10.1111\/jdv.16928.","journal-title":"Acad Dermatol Venereol"},{"key":"1573_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","volume":"25","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH, et al. Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol. 2024;25:655\u201368. https:\/\/doi.org\/10.1007\/s40257-024-00859-y.","journal-title":"Am J Clin Dermatol"},{"key":"1573_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","volume":"23","author":"AS Paller","year":"2021","unstructured":"Paller AS, Wollenberg A, Siegfried E, Tha\u00e7i D, Cork MJ, Arkwright PD, et al. Laboratory safety of dupilumab in patients aged 6\u201311 years with severe atopic dermatitis: results from a phase III clinical trial. Pediatr Drugs. 2021;23:515\u201327. https:\/\/doi.org\/10.1007\/s40272-021-00459-x.","journal-title":"Pediatr Drugs"},{"key":"1573_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40272-022-00553-8","volume":"25","author":"AS Paller","year":"2023","unstructured":"Paller AS, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Gonzalez ME, et al. Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Pediatr Drugs. 2023;25:67\u201377. https:\/\/doi.org\/10.1007\/s40272-022-00553-8.","journal-title":"Pediatr Drugs"},{"key":"1573_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40257-023-00791-7","volume":"24","author":"EC Siegfried","year":"2023","unstructured":"Siegfried EC, Cork MJ, Katoh N, Zhang H, Chuang C-C, Thomas RB, et al. Dupilumab provides clinically meaningful responses in children aged 6\u201311 years with severe atopic dermatitis: post hoc analysis results from a phase III trial. Am J Clin Dermatol. 2023;24:787\u201398. https:\/\/doi.org\/10.1007\/s40257-023-00791-7.","journal-title":"Am J Clin Dermatol"},{"key":"1573_CR33","doi-asserted-by":"publisher","first-page":"00726","DOI":"10.2340\/actadv.v102.854","volume":"102","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Marcoux D, Silverberg JI, Aoki V, Baselga E, Zhang H, et al. Dupilumab provides rapid and sustained improvement in scoring atopic dermatitis outcomes in paediatric patients with atopic dermatitis. Acta Derm Venereol. 2022;102:00726. https:\/\/doi.org\/10.2340\/actadv.v102.854.","journal-title":"Acta Derm Venereol"},{"key":"1573_CR34","doi-asserted-by":"publisher","unstructured":"Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. eClinicalMedicine. 2024;78:102915. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102915","DOI":"10.1016\/j.eclinm.2024.102915"},{"key":"1573_CR35","doi-asserted-by":"publisher","first-page":"e190025","DOI":"10.1001\/jamapediatrics.2019.0025","volume":"173","author":"FD Ramirez","year":"2019","unstructured":"Ramirez FD, Chen S, Langan SM, Prather AA, McCulloch CE, Kidd SA, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr. 2019;173:e190025. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.0025.","journal-title":"JAMA Pediatr"},{"key":"1573_CR36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","volume":"60","author":"S Lewis-Jones","year":"2006","unstructured":"Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema: atopic eczema\/quality of life. Int J Clin Pract. 2006;60:984\u201392. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01047.x.","journal-title":"Int J Clin Pract"},{"key":"1573_CR37","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71:1218\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2014.08.038.","journal-title":"J Am Acad Dermatol"},{"key":"1573_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","volume":"164","author":"J Schmitt","year":"2011","unstructured":"Schmitt J, Von Kobyletzki L, Svensson \u00c5, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials: proactive treatment of eczema: a meta-analysis. Br J Dermatol. 2011;164:415\u201328. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10030.x.","journal-title":"Br J Dermatol"},{"key":"1573_CR39","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/cea.14127","volume":"52","author":"RE Achten","year":"2022","unstructured":"Achten RE, Bakker DS, Van Luijk CM, Van Der Wal M, De Graaf M, Van Wijk F, et al. Ocular surface disease is common in moderate\u2010to\u2010severe atopic dermatitis patients. Clin Experimental Allergy. 2022;52:801\u20135. https:\/\/doi.org\/10.1111\/cea.14127.","journal-title":"Clin Experimental Allergy"},{"key":"1573_CR40","doi-asserted-by":"publisher","unstructured":"Napolitano M, Fabbrocini G, Potestio L, Fontanella G, Picone V, Bennardo L, et al. A 24\u2010weeks real\u2010world experience of dupilumab in adolescents with moderate\u2010to\u2010severe atopic dermatitis. Dermatologic Therapy [Internet]. 2022 [cited 2026 Mar 28];35. https:\/\/doi.org\/10.1111\/dth.15588","DOI":"10.1111\/dth.15588"},{"key":"1573_CR41","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/jdv.18141","volume":"36","author":"L Stingeni","year":"2022","unstructured":"Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Ortoncelli M, et al. Moderate\u2010to\u2010severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real\u2010world experience. Acad Dermatol Venereol. 2022;36:1292\u20139. https:\/\/doi.org\/10.1111\/jdv.18141.","journal-title":"Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01573-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01573-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:44Z","timestamp":1787059964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01573-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01573-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This systematic review was not prospectively registered due to its focused scope on a single therapeutic agent that emerged during the search process.","order":1,"name":"Ethics","label":"Registration Information","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Surma, J. Currier, D. Doyle, M. Maddock, G. Borgman, C. DeGroat, S. Demarinis, N. Aguilar, S. Williams, and P. Fakhoury declare no competing interests. R. Stachler reports serving on the Speaker's Bureau for Sanofi\/Regeneron, AstraZeneca\/Amgen, and Optinose.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of previously published data; no human subjects were enrolled and no ethical approval was required.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data extracted from included studies are presented in the manuscript tables. The datasets analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS, JC, DD, RS: Concept and design. MM, GB, CD, SD, NA, SW, PF: Data collection and screening. JS, SD: Risk of bias assessment, with DD as arbitrator. JS, SD, MM, CD, GB, PF, NA, SW: Data extraction and verification. JS, JC, DD: Manuscript drafting. All authors critically revised the manuscript, read and approved the final version, and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","label":"Authors' Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}